Immune Pharmaceuticals Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 4/11/2018)
| Balance Sheet | Total Assets | 28,608,000.00 | ROE | – |
| Balance Sheet | Total Equity | 13,758,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -28,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -11,587,000.00 | – | – |
| Cashflow | Operating Cash Flow | -11,559,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -2.11 | Div. Yield | – |
| Income | Net Income | -17,889,000.00 | P/E | – |
| Income | Shares Outstanding | 10,000,000.00 | P/B | – |
| Income | Total Revenue | 1.00 | P/S | – |
Ratios calculated on: –
Company Description
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.immunepharma.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more